Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Apr 15, 2021; 13(4): 231-237
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.231
Table 1 Nanotechnology and pancreatic ductal adenocarcinoma early diagnosis
NP type
Main findings
2012Walkey et al[8]Gold, Silica, Polystyrene Characteristics of NPs (material, size, electric charge, hydrophobicity) influence the composition of the PC
2012Monopoli et al[10]Silica, Carbon, Iron oxide, PolystyreneDifferent experimental sources (e.g., plasma, urine), affect the composition of the PC
2013Tenzer et al[9]Silica, PolystyreneEnvironmental factors (e.g., incubation time) influence the composition of PC
2014Caracciolo et al[14]Liposomes After interaction of NPs with plasma of PDACs and non-oncological subjects, differences in the electric charge (zeta potential) and size of the PCs allow to distinguish between the two groups
2015Zheng et al[12]GoldGold-NPs successfully used for early detection of prostate cancer
2017Corbo et al[11]Silica, Polystyrene, Gold, LiposomesDifferent patients affected by different pathological conditions have “personalized” PC
2018Caputo et al[16]LiposomesAnalysis of PCs formed around DOPG liposomes allowed to distinguish patients affected by T1-T2 PDACs from T3s and metastatic ones
2019Künzel et al[13]Silica Successful application of silica NPs in early diagnosis of the head and neck solid squamous carcinoma
2019Papi et al[15]GOAnalysis of BC formed around GO nanoflakes distinguished PDAC from healthy subjects (sensitivity 92%)
Table 2 Nanotechnology and pancreatic ductal adenocarcinoma therapy
NP type
Main Findings
2008Patra et al[19]GoldGold NPs used as nanocarrier improve the effect of cetuximab and gemcitabine in reducing the growth and the proliferation of pancreatic cancer cells in murine model.
2013Mirshafiee et al[21]SilicaThe exposure to human plasma significantly reduces the targeting ability of NPs.
2015Meng et al[24]MSNCoated bilayer MSNs improve the synergic delivery of gemcitabine and paclitaxel in PANC-1 injected in murine models.
2015FDA[20]Liposomal irinotecan (Onivyde®)Approval of Onivyde® for clinical use in metastatic PDAC, who already have received gemcitabine.
2016Liu et al[22]MSNIn KPC pancreatic cancer cells injected into murine models, biocompatibility and therapeutic efficacy of MSNs-irinotecan formulation are superior to liposomal-irinotecan formulation.
2017Lu et al[25]MSNMSNs improve oxaliplatin and indoximod bioavailability in KPC pancreatic cancer cells injected into murine models.
2017Shi et al[23]NP albuminFDA approved the clinical use of NP albumin-bound paclitaxel (Abraxane) for pancreatic cancer.
2020Sadoughi et al[27]ChitosanThe use of chitosan as carrier of gemcitabine and 5-FU improves therapeutic effect decreasing toxicity in pancreatic cancer cells.